Although both prevalence and risk of CLD (Figure 2, Panel A and Panel B) were higher in APOB variant carriers than in non‐carriers across all risk categories (all p ≤ 0.01), the most pronounced difference was observed in individuals with T2D. This evidence concerns the gene APOB and type 2 diabetes mellitus.